Similarly, in 2017 CBL Path sought to address similar issues with the release of Thyroseq® V3 (93). It has an expanded its assay from 56 to 112 genes, detecting mutations, gene fusions, gene expression alterations, and copy number variations. In a prospective double-blind multicenter study using 257 nodules with Bethesda Types III–V (including 11 NIFTP samples, 10 HC carcinomas, 34 HC adenomas, and 5 hyperplastic nodules with HC predominance), Thyroseq® V3 is reported to have an increased diagnostic value, including a Se of 98% (from 96.9%) and specificity of 81.8% (from 74.0%). Moreover, HC samples had an Se and Sp of 100.0 and 66.7%, respectively.